Back to top

Versigent initiated with a Buy at Goldman Sachs

Goldman Sachs initiated coverage of Versigent (VGNT) with a Buy rating and $48 price target implying 20% upside. Versigent is a leading provider of...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE: